{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T15:23:53Z","timestamp":1791559433267,"version":"4.3.4"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"DOI":"10.1007\/s00210-026-05907-4","type":"journal-article","created":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T04:08:16Z","timestamp":1790309296000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Pharmacovigilance and network toxicology analysis of risdiplam-associated adverse events in pediatric patients with spinal muscular atrophy"],"prefix":"10.1007","author":[{"given":"Ben","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingzi","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingqing","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6279-460X","authenticated-orcid":false,"given":"Wei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,25]]},"reference":[{"issue":"14","key":"5907_CR1","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.1093\/hmg\/ddaa126","volume":"29","author":"H Allardyce","year":"2020","unstructured":"Allardyce H, Kuhn D, Hernandez-Gerez E et al (2020) Renal pathology in a mouse model of severe spinal muscular atrophy is associated with downregulation of glial cell-line derived neurotrophic factor (GDNF). Hum Mol Genet 29(14):2365\u20132378. https:\/\/doi.org\/10.1093\/hmg\/ddaa126","journal-title":"Hum Mol Genet"},{"issue":"1","key":"5907_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-32566-x","volume":"16","author":"G Ata","year":"2025","unstructured":"Ata G, Tunal\u0131 Van Den Berg AN, Dansuk E, Kutlut\u00fcrk Y\u0131k\u0131lmaz S, \u00d6ktem S (2025) Inspiratory muscle training and trunk control exercises on respiratory strength and motor function in spinal muscular atrophy: randomized controlled trial. Sci Rep 16(1):2700. https:\/\/doi.org\/10.1038\/s41598-025-32566-x","journal-title":"Sci Rep"},{"issue":"10","key":"5907_CR3","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1056\/NEJMoa2009965","volume":"384","author":"G Baranello","year":"2021","unstructured":"Baranello G, Darras BT, Day JW et al (2021) Risdiplam in type 1 spinal muscular atrophy. N Engl J Med 384(10):915\u2013923. https:\/\/doi.org\/10.1056\/NEJMoa2009965","journal-title":"N Engl J Med"},{"key":"5907_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexmp.2020.104450","volume":"115","author":"X Chen","year":"2020","unstructured":"Chen X, Zhang XB, Li DJ et al (2020) MiR-155 facilitates calcium oxalate crystal-induced HK-2 cell injury via targeting PI3K associated autophagy. Exp Mol Pathol 115:104450. https:\/\/doi.org\/10.1016\/j.yexmp.2020.104450","journal-title":"Exp Mol Pathol"},{"key":"5907_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1657398","author":"Y Cheng","year":"2025","unstructured":"Cheng Y, Zhang M, Yao Y et al (2025) A real-world drug safety surveillance study from the FAERS database of hepatocellular carcinoma patients receiving durvalumab in combination with tremelimumab. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2025.1657398","journal-title":"Front Immunol"},{"issue":"2","key":"5907_CR6","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s40120-023-00444-1","volume":"12","author":"CA Chiriboga","year":"2023","unstructured":"Chiriboga CA, Bruno C, Duong T et al (2023) Risdiplam in patients previously treated with other therapies for spinal muscular atrophy: an interim analysis from the JEWELFISH study. Neurol Ther 12(2):543\u2013557. https:\/\/doi.org\/10.1007\/s40120-023-00444-1","journal-title":"Neurol Ther"},{"issue":"7","key":"5907_CR7","doi-asserted-by":"publisher","first-page":"599","DOI":"10.2165\/11599740-000000000-00000","volume":"35","author":"VR Cornelius","year":"2012","unstructured":"Cornelius VR, Sauzet O, Evans SJW (2012) A signal detection method to detect adverse drug reactions using a parametric time-to-event model in simulated cohort data. Drug Saf 35(7):599\u2013610. https:\/\/doi.org\/10.2165\/11599740-000000000-00000","journal-title":"Drug Saf"},{"issue":"2","key":"5907_CR8","doi-asserted-by":"publisher","first-page":"361","DOI":"10.3233\/JND-230162","volume":"11","author":"N Cornell","year":"2024","unstructured":"Cornell N, Childs AM, Wraige E et al (2024) Risdiplam in spinal muscular atrophy: safety profile and use through the early access to medicine scheme for the paediatric cohort in Great Britain. J Neuromuscul Dis 11(2):361\u2013368. https:\/\/doi.org\/10.3233\/JND-230162","journal-title":"J Neuromuscul Dis"},{"key":"5907_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fdsfr.2023.1323057","volume":"3","author":"PM Cutroneo","year":"2023","unstructured":"Cutroneo PM, Sartori D, Tuccori M et al (2023) Conducting and interpreting disproportionality analyses derived from spontaneous reporting systems. Front Drug Saf Regul 3:1323057. https:\/\/doi.org\/10.3389\/fdsfr.2023.1323057","journal-title":"Front Drug Saf Regul"},{"issue":"5","key":"5907_CR10","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1056\/NEJMoa2102047","volume":"385","author":"BT Darras","year":"2021","unstructured":"Darras BT, Masson R, Mazurkiewicz-Be\u0142dzi\u0144ska M et al (2021) Risdiplam-treated infants with type 1 spinal muscular atrophy versus historical controls. N Engl J Med 385(5):427\u2013435. https:\/\/doi.org\/10.1056\/NEJMoa2102047","journal-title":"N Engl J Med"},{"issue":"7S","key":"5907_CR11","doi-asserted-by":"publisher","first-page":"7S29","DOI":"10.1016\/S0929-693X(20)30274-8","volume":"27","author":"B Fauroux","year":"2020","unstructured":"Fauroux B, Griffon L, Amaddeo A et al (2020) Respiratory management of children with spinal muscular atrophy (SMA). Arch Pediatr 27(7S):7S29-27S34. https:\/\/doi.org\/10.1016\/S0929-693X(20)30274-8","journal-title":"Arch Pediatr"},{"issue":"18","key":"5907_CR12","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","volume":"377","author":"RS Finkel","year":"2017","unstructured":"Finkel RS, Mercuri E, Darras BT et al (2017) Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med 377(18):1723\u20131732. https:\/\/doi.org\/10.1056\/NEJMoa1702752","journal-title":"N Engl J Med"},{"issue":"7","key":"5907_CR13","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1056\/NEJMoa2410120","volume":"393","author":"RS Finkel","year":"2025","unstructured":"Finkel RS, Servais L, Vlodavets D et al (2025) Risdiplam in presymptomatic spinal muscular atrophy. N Engl J Med 393(7):671\u2013682. https:\/\/doi.org\/10.1056\/NEJMoa2410120","journal-title":"N Engl J Med"},{"key":"5907_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1226969","volume":"14","author":"Q Giorgia","year":"2023","unstructured":"Giorgia Q, Gomez Garcia de la Banda M, Smeriglio P (2023) Role of circulating biomarkers in spinal muscular atrophy: insights from a new treatment era. Front Neurol 14:1226969. https:\/\/doi.org\/10.3389\/fneur.2023.1226969","journal-title":"Front Neurol"},{"issue":"1","key":"5907_CR15","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1002\/ppul.25142","volume":"56","author":"M G\u00f3mez-Garc\u00eda de la Banda","year":"2021","unstructured":"G\u00f3mez-Garc\u00eda de la Banda M, Amaddeo A, Khirani S et al (2021) Assessment of respiratory muscles and motor function in children with SMA treated by nusinersen. Pediatr Pulmonol 56(1):299\u2013306. https:\/\/doi.org\/10.1002\/ppul.25142","journal-title":"Pediatr Pulmonol"},{"issue":"2","key":"5907_CR16","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1002\/ppul.26218","volume":"58","author":"W Guo","year":"2023","unstructured":"Guo W, Meng L, Cao L (2023) Risk factors for recurrent respiratory tract infections and acute respiratory failure in children with spinal muscular atrophy. Pediatr Pulmonol 58(2):507\u2013515. https:\/\/doi.org\/10.1002\/ppul.26218","journal-title":"Pediatr Pulmonol"},{"key":"5907_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1702257","volume":"16","author":"K Ji","year":"2004","unstructured":"Ji K, Huang X, Wang F et al (2004) Comparative safety profiles of spironolactone, eplerenone, and finerenone: a pharmacovigilance study based on FAERS data from 2004 to 2024. Front Pharmacol 16:1702257. https:\/\/doi.org\/10.3389\/fphar.2025.1702257","journal-title":"Front Pharmacol"},{"issue":"6","key":"5907_CR18","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1002\/acn3.51560","volume":"9","author":"JM Kwon","year":"2022","unstructured":"Kwon JM, Arya K, Kuntz N et al (2022) An expanded access program of risdiplam for patients with type 1 or 2 spinal muscular atrophy. Ann Clin Transl Neurol 9(6):810\u2013818. https:\/\/doi.org\/10.1002\/acn3.51560","journal-title":"Ann Clin Transl Neurol"},{"key":"5907_CR19","doi-asserted-by":"publisher","first-page":"1366943","DOI":"10.3389\/fped.2024.1366943","volume":"12","author":"L Lagae","year":"2024","unstructured":"Lagae L, Proesmans M, Van den Hauwe M, Vermeulen F, De Waele L, Boon M (2024) Respiratory morbidity in patients with spinal muscular atrophy-a changing world in the light of disease-modifying therapies. Front Pediatr 12:1366943. https:\/\/doi.org\/10.3389\/fped.2024.1366943","journal-title":"Front Pediatr"},{"issue":"10","key":"5907_CR20","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000047993","volume":"105","author":"Y Li","year":"2026","unstructured":"Li Y, Zhang W, Tang L et al (2026) Core targets of bisphenol A in cervical cancer revealed by network toxicology and molecular docking. Medicine (Baltimore) 105(10):e47993. https:\/\/doi.org\/10.1097\/MD.0000000000047993","journal-title":"Medicine (Baltimore)"},{"issue":"W1","key":"5907_CR21","doi-asserted-by":"publisher","first-page":"W159","DOI":"10.1093\/nar\/gkac394","volume":"50","author":"Y Liu","year":"2022","unstructured":"Liu Y, Yang X, Gan J, Chen S, Xiao ZX, Cao Y (2022a) CB-Dock2: improved protein\u2013ligand blind docking by integrating cavity detection, docking and homologous template fitting. Nucleic Acids Res 50(W1):W159\u2013W164. https:\/\/doi.org\/10.1093\/nar\/gkac394","journal-title":"Nucleic Acids Res"},{"key":"5907_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.818625","volume":"13","author":"Y Liu","year":"2022","unstructured":"Liu Y, Sun Y, Kang J et al (2022b) Role of ROS-induced NLRP3 inflammasome activation in the formation of calcium oxalate nephrolithiasis. Front Immunol 13:818625. https:\/\/doi.org\/10.3389\/fimmu.2022.818625","journal-title":"Front Immunol"},{"issue":"9","key":"5907_CR23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0310947","volume":"19","author":"J Liu","year":"2024","unstructured":"Liu J, Liu X, Guo L et al (2024) PPAR\u03b3 agonist alleviates calcium oxalate nephrolithiasis by regulating mitochondrial dynamics in renal tubular epithelial cell. PLoS ONE 19(9):e0310947. https:\/\/doi.org\/10.1371\/journal.pone.0310947","journal-title":"PLoS ONE"},{"issue":"12","key":"5907_CR24","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1016\/S1474-4422(22)00339-8","volume":"21","author":"R Masson","year":"2022","unstructured":"Masson R, Mazurkiewicz-Be\u0142dzi\u0144ska M, Rose K et al (2022) Safety and efficacy of risdiplam in patients with type 1 spinal muscular atrophy (FIREFISH part 2): secondary analyses from an open-label trial. Lancet Neurol 21(12):1110\u20131119. https:\/\/doi.org\/10.1016\/S1474-4422(22)00339-8","journal-title":"Lancet Neurol"},{"issue":"18","key":"5907_CR25","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","volume":"377","author":"JR Mendell","year":"2017","unstructured":"Mendell JR, Al-Zaidy S, Shell R et al (2017) Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med 377(18):1713\u20131722. https:\/\/doi.org\/10.1056\/NEJMoa1706198","journal-title":"N Engl J Med"},{"issue":"1","key":"5907_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-022-00380-8","volume":"8","author":"E Mercuri","year":"2022","unstructured":"Mercuri E, Sumner CJ, Muntoni F, Darras BT, Finkel RS (2022a) Spinal muscular atrophy. Nat Rev Dis Primers 8(1):52. https:\/\/doi.org\/10.1038\/s41572-022-00380-8","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"5907_CR27","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/S1474-4422(21)00367-7","volume":"21","author":"E Mercuri","year":"2022","unstructured":"Mercuri E, Deconinck N, Mazzone ES et al (2022b) Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial. Lancet Neurol 21(1):42\u201352. https:\/\/doi.org\/10.1016\/S1474-4422(21)00367-7","journal-title":"Lancet Neurol"},{"issue":"5","key":"5907_CR28","doi-asserted-by":"publisher","DOI":"10.1212\/NXG.0000000000000353","volume":"5","author":"FC Nery","year":"2019","unstructured":"Nery FC, Siranosian JJ, Rosales I et al (2019) Impaired kidney structure and function in spinal muscular atrophy. Neurol Genet 5(5):e353. https:\/\/doi.org\/10.1212\/NXG.0000000000000353","journal-title":"Neurol Genet"},{"issue":"5","key":"5907_CR29","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1007\/s00415-023-11560-1","volume":"270","author":"M Oskoui","year":"2023","unstructured":"Oskoui M, Day JW, Deconinck N et al (2023) Two-year efficacy and safety of risdiplam in patients with type 2 or non-ambulant type 3 spinal muscular atrophy (SMA). J Neurol 270(5):2531\u20132546. https:\/\/doi.org\/10.1007\/s00415-023-11560-1","journal-title":"J Neurol"},{"issue":"6","key":"5907_CR30","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.447","volume":"6","author":"A Poirier","year":"2018","unstructured":"Poirier A, Weetall M, Heinig K et al (2018) Risdiplam distributes and increases SMN protein in both the central nervous system and peripheral organs. Pharmacol Res Perspect 6(6):e00447. https:\/\/doi.org\/10.1002\/prp2.447","journal-title":"Pharmacol Res Perspect"},{"key":"5907_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2026.1772885","volume":"17","author":"G Qiu","year":"2026","unstructured":"Qiu G, Ye D, Xu X (2026) Post-market safety profile and suicide risk signals of vortioxetine: a real-world pharmacovigilance study. Front Pharmacol 17:1772885. https:\/\/doi.org\/10.3389\/fphar.2026.1772885","journal-title":"Front Pharmacol"},{"issue":"15","key":"5907_CR32","doi-asserted-by":"publisher","first-page":"6501","DOI":"10.1021\/acs.jmedchem.8b00741","volume":"61","author":"H Ratni","year":"2018","unstructured":"Ratni H, Ebeling M, Baird J et al (2018) Discovery of risdiplam, a selective survival of motor neuron-2 (SMN2) gene splicing modifier for the treatment of spinal muscular atrophy (SMA). J Med Chem 61(15):6501\u20136517. https:\/\/doi.org\/10.1021\/acs.jmedchem.8b00741","journal-title":"J Med Chem"},{"issue":"5","key":"5907_CR33","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1007\/s40120-025-00795-x","volume":"14","author":"K Saito","year":"2025","unstructured":"Saito K, Saito T, Arakawa R et al (2025) Safety of risdiplam in Japanese patients with spinal muscular atrophy: a 12\u2011month interim analysis of a postmarketing surveillance study. Neurol Ther 14(5):2083\u20132094. https:\/\/doi.org\/10.1007\/s40120-025-00795-x","journal-title":"Neurol Ther"},{"key":"5907_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.889088","volume":"13","author":"O Sauzet","year":"2022","unstructured":"Sauzet O, Cornelius V (2022) Generalised weibull model-based approaches to detect non-constant hazard to signal adverse drug reactions in longitudinal data. Front Pharmacol 13:889088. https:\/\/doi.org\/10.3389\/fphar.2022.889088","journal-title":"Front Pharmacol"},{"issue":"10","key":"5907_CR35","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1002\/pds.4790","volume":"28","author":"JHG Scholl","year":"2019","unstructured":"Scholl JHG, van Hunsel FPAM, Hak E, van Puijenbroek EP (2019) Time to onset in statistical signal detection revisited: a follow-up study in long-term onset adverse drug reactions. Pharmacoepidemiol Drug Saf 28(10):1283\u20131289. https:\/\/doi.org\/10.1002\/pds.4790","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"5907_CR36","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s13023-022-02227-7","volume":"17","author":"ES Veldhoen","year":"2022","unstructured":"Veldhoen ES, Wijngaarde CA, Hulzebos EHJ et al (2022) Natural history of respiratory muscle strength in spinal muscular atrophy: a prospective national cohort study. Orphanet J Rare Dis 17(1):70. https:\/\/doi.org\/10.1186\/s13023-022-02227-7","journal-title":"Orphanet J Rare Dis"},{"key":"5907_CR37","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2026.1757807","volume":"17","author":"X Wang","year":"2026","unstructured":"Wang X, Han S, Huang Y et al (2026) An integrative pharmacovigilance, network toxicology and molecular docking study on drug-induced cheilitis. Front Pharmacol 17:1757807. https:\/\/doi.org\/10.3389\/fphar.2026.1757807","journal-title":"Front Pharmacol"},{"issue":"2","key":"5907_CR38","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/S1474-4422(23)00419-2","volume":"23","author":"CJJ Yeo","year":"2024","unstructured":"Yeo CJJ, Tizzano EF, Darras BT (2024) Challenges and opportunities in spinal muscular atrophy therapeutics. Lancet Neurol 23(2):205\u2013218. https:\/\/doi.org\/10.1016\/S1474-4422(23)00419-2","journal-title":"Lancet Neurol"},{"issue":"3","key":"5907_CR39","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0298609","volume":"19","author":"L Yu","year":"2024","unstructured":"Yu L, Liu L (2024) Exploration of adverse events associated with risdiplam use: retrospective cases from the US Food and Drug Administration Adverse Event Reporting System (FAERS) database. PLoS ONE 19(3):e0298609. https:\/\/doi.org\/10.1371\/journal.pone.0298609","journal-title":"PLoS ONE"},{"key":"5907_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2023.1152318","volume":"11","author":"ZJ Zhong","year":"2023","unstructured":"Zhong ZJ, Zheng PM, Dou HH, Wang JG (2023) Adverse events in the treatment of spinal muscular atrophy in children and adolescents with nusinersen: a systematic review and meta-analysis. Front Pediatr 11:1152318. https:\/\/doi.org\/10.3389\/fped.2023.1152318","journal-title":"Front Pediatr"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05907-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-026-05907-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05907-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T04:08:17Z","timestamp":1790309297000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-026-05907-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,25]]},"references-count":40,"alternative-id":["5907"],"URL":"https:\/\/doi.org\/10.1007\/s00210-026-05907-4","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,25]]},"assertion":[{"value":"26 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study involves a secondary analysis of publicly accessible summary statistics and does not necessitate explicit ethical approval.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}